Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Tiberi

Showing results (81-90 of 147) with videos related to

Pageof 15
Sort By:
The European Respiratory Journal|July 11, 2015
Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective studyMathieu S Bolhuis, Simon Tiberi, Giovanni Sotgiu, et al.
Archivos De Bronconeumologia|June 26, 2022
Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID LungsEmanuele Pontali, Denise Rossato Silva, Florian M Marx, et al.
Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia|May 24, 2018
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosisDenise Rossato Silva, Margareth Dalcolmo, Simon Tiberi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 8, 2016
Classifying new anti-tuberculosis drugs: rationale and future perspectivesSimon Tiberi, Anna Scardigli, Rosella Centis, et al.
American Journal of Respiratory and Critical Care Medicine|March 22, 2017
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not CureMartin J Dedicoat, Gunar Günther, Valeriu Crudu, et al.
The European Respiratory Journal|September 22, 2012
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TBSaverio De Lorenzo, Jan Wilem Alffenaar, Giovanni Sotgiu, et al.
Pulmonology|February 6, 2021
Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidenceGiovanni Battista Migliori, Dina Visca, Martin van den Boom, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2018
Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulationJames Millard, Henry Pertinez, Laura Bonnett, et al.
The New England Journal of Medicine|February 18, 2026
Revival of Ethionamide by AlpibectirMichel Pieren, Glenn E Dale, Marc Gitzinger, et al.
International Journal of Antimicrobial Agents|April 9, 2017
Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosisJasper Kamp, Mathieu S Bolhuis, Simon Tiberi, et al.
Pageof 15

Showing results (81-90 of 147) with videos related to

Sort By:
Pageof 15
The European Respiratory Journal|July 11, 2015
Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective studyMathieu S Bolhuis, Simon Tiberi, Giovanni Sotgiu, et al.
Archivos De Bronconeumologia|June 26, 2022
Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID LungsEmanuele Pontali, Denise Rossato Silva, Florian M Marx, et al.
Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia|May 24, 2018
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosisDenise Rossato Silva, Margareth Dalcolmo, Simon Tiberi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 8, 2016
Classifying new anti-tuberculosis drugs: rationale and future perspectivesSimon Tiberi, Anna Scardigli, Rosella Centis, et al.
American Journal of Respiratory and Critical Care Medicine|March 22, 2017
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not CureMartin J Dedicoat, Gunar Günther, Valeriu Crudu, et al.
The European Respiratory Journal|September 22, 2012
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TBSaverio De Lorenzo, Jan Wilem Alffenaar, Giovanni Sotgiu, et al.
Pulmonology|February 6, 2021
Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidenceGiovanni Battista Migliori, Dina Visca, Martin van den Boom, et al.
The Journal of Antimicrobial Chemotherapy|March 28, 2018
Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulationJames Millard, Henry Pertinez, Laura Bonnett, et al.
The New England Journal of Medicine|February 18, 2026
Revival of Ethionamide by AlpibectirMichel Pieren, Glenn E Dale, Marc Gitzinger, et al.
International Journal of Antimicrobial Agents|April 9, 2017
Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosisJasper Kamp, Mathieu S Bolhuis, Simon Tiberi, et al.
Pageof 15